Building behavioural science into HIV prevention
%2Ffile%2Fattachments%2Forphans%2FLenStory_962976.jpg&w=3840&q=75)
South Africa has introduced Lenacapavir, a twice-yearly injectable form of PrEP that offers nearly 100% effectiveness in preventing HIV. Health experts are now focusing on integrating this new tool into existing sexual and reproductive health services to improve accessibility.
Why it matters
This represents a major scientific breakthrough in HIV prevention, potentially shifting the burden of care from daily pills to a more manageable long-term injectable regimen.
Lenacapavir (LEN) has arrived in South Africa, and this injectable form of pre-exposure prophylaxis (PrEP) marks a major scientific milestone as it promises a near 100% effectiveness in preventing HIV. But there is a need to integrate injectable PrEP into broader sexual and reproductive health services.
The article reports on medical advancements and public health policy in a factual, objective manner.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in